Skip to product information
1 of 1

MULTI SCIENCES

Human IL-1alpha ELISA Assay Kit

Human IL-1alpha ELISA Assay Kit

SKU:EK101A

Regular price Send Inquiry
Regular price Sale price Send Inquiry
Sale Sold out
View full details

Product Details

Human IL-1alpha ELISA Assay Kit

Brand

MultiSciences

CatNum

70-EK101A

Product Name

Human IL-1alpha ELISA Kit

Customs Name

Human IL-1alpha ELISA Kit

Application

ELISA

Reactivity

Human

Assay Type

Sandwich ELISA

Suitable Sample Type

serum, plasma, cell culture supernates

Format

96-well strip plate

Storage

4℃ (unopened) standard stored at -20℃, others stored at 4℃ (opened)

Shipping Condition

4℃

Sample Volume

50 μl

Sensitivity

0.52 pg/ml

Standard Curve Range

7.81 - 500 pg/ml

Spike Recovery Range

81 % - 106 %

Mean Spike Recovery

0.93

CV of Intra plate

2.5 % - 4.4 %

CV of Inter plate

3.1 % - 6.8 %

Release Date

2015/4/1

Components

96-well polystyrene microplate coated with a monoclonal antibody against IL-1α
Human IL-1α Standard, lyophilized
IL-1α Detect Antibody
Standard Diluent
Streptavidin-HRP
Assay Buffer (10×)
Substrate (TMB)
Stop Solution
Washing Buffer (20×)
Plate Covers

Describtion

This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human IL-1α. The Human IL-1α ELISA is for research use only. Not for diagnostic or therapeutic procedures.
Interleukin-1 (IL-1) is an extracellular peptide of 17 kDa that designates two proteins, IL-1α and IL-1β. In general, Interleukin 1 is responsible for the production of inflammation, as well as the promotion of fever and sepsis.IL-1α inhibitors are being developed to interrupt those processes and treat diseases.IL-1α is produced mainly by activated macrophages, as well asneutrophils, epithelial cells, and endothelial cells. It possesses metabolic, physiological, haematopoietic activities, and plays one of the central roles in the regulation of the immune responses. It binds to the interleukin-1 receptor. It is on the pathway that activates tumor necrosis factor-alpha.
IL-1α has been administered to patients during receiving autologous bone marrow transplantation. There is currently a head and neck phase III trial being run by Cel-Sci Corp. involving IL-1αand many other interleukins (Multikine) as an immunotherapy. In dermatology and cosmetics topical IL-1α has been shown to increase the production of collagen and other components of the dermal matrix.